Skip to main content
Caplight Logo









Abvance Therapeutics

Abvance Therapeutics

Private
Reno, NevadaHealthcare & Life Scienceshttps://abvancetherapeutics.com/

Last Round

Seed

Jun 24, 2025

Total Funding Raised

$3.9M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Abvance Therapeutics is a biotechnology company developing glucagon-based therapies designed to prevent hypoglycemia and improve glucose management for diabetes patients.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticaldiabetes managementinsulin therapyhypoglycemiadrug developmentcombination therapypeptide drugglycemic controlbiotech startuppreclinical researchdiabetes techdrug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Abvance Therapeutics Comparables

Compare Abvance Therapeutics with similar companies based on industry and business-model similarity.

Abvance Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Zucara Therapeutics Inc.
78%
Sensulin
78%
Zealand Pharma
71%

Abvance Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedJun 24, 2025
DebtSep 10, 2024

Key People

Founding team and executive leadership

Edward Raskin

Chief Executive Officer

Executive Team

Abvance Therapeutics Investors

Notable investors and investment history

Abvance Therapeutics investors
InvestorRounds
Helmsley Charitable TrustDebt
Zubi CapitalSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors increased 93% MoM.

  • Jul 28, 2026

    Monthly visitors increased 55% MoM.

Abvance Therapeutics Filings

Explore SEC and related filing metadata, where available.

Abvance Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Abvance Therapeutics's valuation, stock price, and market status.

Is Abvance Therapeutics a public or private company?

Abvance Therapeutics is a private company.

What is the current stock price of Abvance Therapeutics?

Abvance Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Abvance Therapeutics worth (valuation)?

Valuation information for Abvance Therapeutics is not publicly available.

Can I buy Abvance Therapeutics stock?

Abvance Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Abvance Therapeutics's last funding round?

Abvance Therapeutics's most recent funding round was Seed on June 24, 2025.

Who are the main investors in Abvance Therapeutics?

Key investors in Abvance Therapeutics include Zubi Capital.

Will Abvance Therapeutics IPO soon?

No public IPO plans have been announced for Abvance Therapeutics.

How can I track Abvance Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Abvance Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersReno, Nevada
Employee Range7
Year Founded2016
Last FundingJun 24, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?